Aldeyra Therapeutics, Inc. acquired Helio Vision, Inc. for $25 million.
January 28, 2019
Share
Aldeyra Therapeutics, Inc. entered into a definitive agreement to acquire Helio Vision, Inc. for $25 million on January 24, 2019. In consideration Aldeyra Therapeutics, Inc. will initially issue 1,150,990 shares of its common stock at closing of the transaction, $2.5 million of Common Stock on the date that is 24 months following the Closing Date, $10 million of Common Stock prior to the 10th anniversary of the Closing Date and $2.5 million of Common Stock following NDA Approval of an indication prior to the 12th anniversary of the Closing Date provided that the aggregate Merger Consideration shall not exceed $25 million and in no event shall the Company be obligated to issue more than 5,248,885 shares of Common Stock. The transaction is subject to the approval of the Helio Vision, Inc. shareholders. The transaction is approved by the board of directors of Helio Vision, Inc. and Aldeyra Therapeutics, Inc.Jay K. Hachigian and Keith J. Scherer of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisor for Aldeyra Therapeutics, Inc. Stuart M. Cable and Robert E. Bishop of Goodwin Procter LLP acted as legal advisor for Helio Vision, Inc.
Aldeyra Therapeutics, Inc. completed the acquisition of Helio Vision, Inc. on January 28, 2019.
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.